Zura Bio Ltd expected to post a loss of 20 cents a share - Earnings Preview

Zura Bio

10/08/2026 14:49

Zura Bio Ltd ZURA.OQ ZURA.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Zura Bio Ltd is for a loss of 20 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Zura Bio Ltd is $15.50, about 159.8% above its last closing price of $5.97
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.17
-0.17
-0.22
Missed
-26.4
Dec. 31 2026
-0.16
-0.20
-0.49
Missed
-149.4
Sep. 30 2025
-0.17
-0.18
-0.21
Missed
-15.7​
Jun. 30 2025
-0.18
-0.19
-0.17
Beat
9.7
​​Mar. 31 2025
-0.15
-0.16
-0.19
Missed
-19.8
Dec. 31 2024
-0.16
-0.10
Beat
35.6​
Sep. 30 2024
-0.12
-0.12
-0.26
Missed
-110.8
Jun. 30 2024
-0.16
-0.15
-0.17
Missed
-13.5
This summary was machine generated August 10 at 13:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)